EANS-News: AGENNIX AG Appoints New Vice President of Clinical Development

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Subtitle: Dr. Steven Simonson Hired to Lead Talactoferrin Sepsis Development
Program

Planegg/Munich (Germany), Princeton, NJ, USA and Houston, TX, USA (euro adhoc) -
Agennix AG (Frankfurt Stock Exchange: AGX) today announced the appointment of
Steven Simonson, M.D., M.H.S. as Vice President, Clinical Development, reporting
to Dr. Rajesh Malik, the Company's Chief Medical Officer. In this newly-created
position, Dr. Simonson will lead the Company's sepsis development program with
oral talactoferrin.

Rajesh Malik, M.D., Chief Medical Officer, said, "I am delighted to have Dr.
Simonson join the team at Agennix. He has extensive clinical, academic and
industry experience, including running a sepsis clinical development program at
a major international pharmaceutical company. He joins us at a critical time as
we prepare to initiate our Phase II/III trial with talactoferrin in severe
sepsis."

Dr. Simonson has fifteen years of pharmaceutical industry experience. Prior to
joining Agennix, Dr. Simonson held several senior positions at AstraZeneca, most
recently as Senior Director, Clinical Research, Infection Therapeutic Area. In
this position, he served as the lead physician for a Phase II program in sepsis.
Prior to his industry career, Dr. Simonson held several academic positions at
Duke University Medical Center. He received his M.D. from Medical College of
Wisconsin and a Masters degree in Health Sciences from Duke University School of
Medicine. He is Board certified in Pulmonary, Critical Care and Internal
Medicine.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral therapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as well as in
severe sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program further
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical
gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. There can be no
guarantee that the Company will move talactoferrin forward in development for
severe sepsis in a timely manner, if at all, or that talactoferrin will
ultimately be approved for sale in any indication in any country.
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Agennix AG
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Tel.: +49 89 8565-2693
[email protected]

In the USA: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Tel.: 609-524-5884
[email protected]

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Tel.: +49 89 210 228 0
[email protected]

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Tel.: +44 207 936 9325
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: [email protected]
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print